Arix Bioscience PLC
Peregrine has extensive experience in investment management and investment banking. In his past career, Mr Moncreiffe held various corporate finance and trading positions in New York, London and East Asia within the Credit Suisse First Boston (CSFB) group over a ten year period, ending up as an Executive Director of CSFB in London in 1982. He held a number of trading management roles at Lehman Brothers as a Managing Director in New York and London until 1986 when he joined E F Hutton as Managing Director of International Capital Markets before it was acquired by Shearson Lehman in 1988. From 1990 to 2000 he was Chief Executive Officer of Buchanan Partners Ltd, a proprietary investment company which he co-founded. In 1998 he became Chairman of UA Group, the agricultural services and property investment business sold to Elphinstone in 2005. He was appointed as Chairman of North Atlantic Smaller Companies Investment Trust in 2008, having previously been a Director of the Company from 1993 – 2006 and is a director of Metage Funds Limited. Peregrine received an undergraduate degree from the University of Oxford.
Peregrine also sits on the Strategy & Investment, Audit, Nomination and Remuneration Committees for Ar
This person is not in the org chart
This person is not in any teams
This person is not in any offices
Arix Bioscience PLC
Arix Bioscience plc is a United Kingdom-based healthcare and life science company. The Company is a holding company that is focused on generating value from the development and commercialization of technologies and discoveries. Its principal activity is to source, finance and develop healthcare and life science businesses across the world. The Company focuses on acquiring interests in, and provide operational oversight to, healthcare and life science businesses with which it partners in the healthcare and life science sector. The Company holds interests in BioMotiv, OptiKira LLC, Autolus, Depixus SAS, Verona Pharma plc and Artios Pharma Ltd. The Company has agreements with universities in the United Kingdom, Europe and Australia, providing direct access to new technologies. It also has access to a range of research projects from the United States academic institutions. Its subsidiaries include Arix Bioscience Holdings Limited, Arix US Inc and Arthurian Life Sciences GP Limited.